Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Primary Myelofibrosis 16Polycythemia Vera 14Myeloproliferative Disorders 11Leukemia, Myeloid, Acute 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia 6Myelodysplastic Syndromes 5Hematologic Diseases 5Myelodysplastic-Myeloproliferative Diseases 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Graft vs Host Disease 4Bone Marrow Diseases 4Thrombocythemia, Essential 3Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Thrombocytosis 2Pancreatic Neoplasms 2Multiple Myeloma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Bronchiolitis Obliterans Syndrome 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Preleukemia 1Precancerous Conditions 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1

Interventions

Gemcitabine 74Capecitabine 60Paclitaxel 59Fluorouracil 58Oxaliplatin 57Bevacizumab 51Docetaxel 50Leucovorin 48Nivolumab 40Cisplatin 40Irinotecan 39Carboplatin 37Cetuximab 34pembrolizumab 32Radiosurgery 32Trastuzumab 30Radiotherapy 27Everolimus 24Sorafenib 23Pemetrexed 20Doxorubicin 20Albumin-Bound Paclitaxel 20Ipilimumab 19Cyclophosphamide 19Panitumumab 18Zoledronic Acid 17Lapatinib 17Erlotinib Hydrochloride 17Prednisone 16pazopanib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasm Metastasis × ruxolitinib × Clear all
NCT02142036 2019-03-13

MetAction

Oslo University Hospital

Phase 2 Completed
50 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡